Rheumatoid arthritis

@article{Smolen2016RheumatoidA,
  title={Rheumatoid arthritis},
  author={Josef S. Smolen and Daniel Aletaha and Iain B. McInnes},
  journal={The Lancet},
  year={2016},
  volume={388},
  pages={2023-2038}
}
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor outcomes such as high disease activity, presence of autoantibodies, and early joint damage. Treatment algorithms involve measuring disease activity with composite indices, applying a treatment-to-target strategy, and use of conventional… Expand
Pharmacologic Management of Rheumatoid Arthritis
TLDR
Treatment options for patients with rheumatoid arthritis include nonpharmacologic therapy, which includes rest, occupational and physical therapy, and weight reduction and use of assistive devices, as necessary. Expand
Predicting and monitoring disease course in rheumatoid arthritis : imaging, biomarkers, risk factors, and integrative medicine
TLDR
Findings support the value of incorporating personalized integrative medicine into clinical practice for patients with RA and suggest that allopathic practice can move towards even better proactive patient care in RA. Expand
Rheumatoid arthritis
TLDR
DMARDs are currently used to suppress immune abnormalities and to control disease activity and have been shown to prevent the progression of joint destruction and physical dysfunction over a long period. Expand
Diagnosis and Management of Rheumatoid Arthritis: A Review
TLDR
A treat-to-target strategy aimed at reducing disease activity by at least 50% within 3 months and achieving remission or low disease activity within 6 months, with sequential drug treatment if needed, can prevent RA-related disability. Expand
Rheumatoid arthritis
TLDR
The improved understanding of the pathogenetic processes involved, rational use of established drugs and development of new drugs and reliable assessment tools have drastically altered the lives of individuals with RA over the past 2 decades. Expand
Risk Factors for Developing Rheumatoid Arthritis in Patients With Undifferentiated Arthritis and Inflammatory Arthralgia
TLDR
This review aims to give an overview of clinical risk factors for developing RA, both in suspected arthralgia and in undifferentiated arthritis, taking into consideration the role of serological markers (immunological and acute phase reactants) and clinical features assessed at consultation such as: articular affection and patient's clinical perception. Expand
Clinical remission in rheumatoid arthritis and psoriatic arthritis.
TLDR
A narrative review of the different criteria of remission, in the light of the available treatment strategies for RA and PsA, and in the attempt to provide rheumatologists an opportunity to improve the outcome to the greatest extent possible in their clinical practice. Expand
Beyond the joints, the extra-articular manifestations in rheumatoid arthritis.
TLDR
The extra-articular features of RA remain, despite the improvement of joint damage, a major diagnostic and therapeutic challenge, since these are associated with a poor prognosis and need to be early recognized and promptly managed. Expand
The autoimmune response as a potential target for tolerance induction before the development of rheumatoid arthritis
TLDR
The autoimmune response underlying rheumatoid arthritis-specific autoimmunity develops and evolves during the transition from health to disease, and how tolerance studies could be designed to achieve prevention or cure of the disease is reviewed. Expand
Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach
TLDR
Avoiding a refractory course is best achieved by following proven management paradigms (e.g. early diagnosis and treat-to-target), addressing modifiable risk factors, and considering enrolment in novel trials. Expand
...
1
2
3
4
5
...

References

SHOWING 1-6 OF 6 REFERENCES
Rheumatoid arthritis.
TLDR
Gene-environment interactions appear as the most plausible underlying cause of RA, and age, sex, smoking, shared epitope and others correlate with its RA. Expand
Genetics and epigenetics of rheumatoid arthritis
TLDR
The major advances in identifying RA genetic susceptibility markers both within and outside of the MHC are reviewed and current knowledge of the role of epigenetics in RA susceptibility is reviewed. Expand
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
TLDR
Seven new rheumatoid arthritis risk alleles were identified at genome-wide significance (P < 5 × 10−8) in an analysis of all 41,282 samples, and an additional 11 SNPs replicated at P < 0.05, suggesting that most represent genuine rhearatoid arthritisrisk alleles. Expand
High density genetic mapping identifies new susceptibility loci for rheumatoid arthritis
TLDR
This study illustrates the advantages of dense SNP mapping analysis to inform subsequent functional investigations and refined the peak of association to a single gene for 19 loci, identified secondary independent effects at 6 loci and identified association to low-frequency variants at 4 loci. Expand
Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis
TLDR
Imputation of functional variation from large reference panels can help fine map association signals in the MHC, and three amino acid positions in HLA-DRβ1, which are all located in peptide-binding grooves, almost completely explain the M HC association to rheumatoid arthritis risk. Expand
Rare, low-frequency, and common variants in the protein-coding sequence of biological candidate genes from GWASs contribute to risk of rheumatoid arthritis.
TLDR
The results indicate that variants within the protein-coding portion of a subset of biological candidate genes identified by GWASs contribute to the risk of RA. Expand